|
KMID : 0620920120440010026
|
|
Experimental & Molecular Medicine
2012 Volume.44 No. 1 p.26 ~ p.35
|
|
|
Experimental and Molecular Medicine
|
|
Kim Bo-Na
Yoon Byung-Sun
Moon Jai-Hee
Kim Jong-Gun
Jun Eun-Kyoung
Lee Jung-Han
Kim Jun-Sung
Baik Cheong-Soon
Kim Ae-Ree
Whang Kwang-Youn
You Seung-Kwon
|
|
|
Abstract
|
|
|
|
Recent evidence has suggested that human skin fibroblasts may represent a novel source of therapeutic stem cells. In this study, we report a 3-stage method to induce the differentiation of skin fibroblasts into insulin-producing cells (IPCs). In stage 1, we establish the isolation, expansion and characterization of mesenchymal stem cells from human labia minora dermis-derived fibroblasts (hLMDFs) (stage 1: MSC expansion). hLMDFs express the typical mesenchymal stem cell marker proteins and can differentiate into adipocytes, osteoblasts, chondrocytes or muscle cells. In stage 2, DMEM/F12 serum-free medium with ITS mix (insulin, transferrin, and selenite) is used to induce differentiation of hLMDFs into endoderm-like cells, as determined by the expression of the endoderm markers Sox17, Foxa2, and PDX1 (stage 2: mesenchymal-endoderm transition). In stage 3, cells in the mesenchymal-endoderm transition stage are treated with nicotinamide in order to further differentiate into self-assembled, 3-dimensional islet cell-like clusters that express multiple genes related to pancreatic β-cell development and function (stage 3: IPC). We also found that the transplantation of IPCs can normalize blood glucose levels and rescue glucose homeostasis in streptozotocin-induced diabetic mice. These results indicate that hLMDFs have the capacity to differentiate into functionally competent IPCs and represent a potential cell-based treatment for diabetes mellitus.
|
|
|
KEYWORD
|
|
|
cell differentiation, dermis, endoderm, fibroblasts, humans, insulin, mesenchymal stem cells
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|